Protalix Biotherapeutics Inc (NYSE MKT:PLX) — Stock Price

$2.10 USD
▲ 3.45% today

Protalix Biotherapeutics Inc (NYSE MKT:PLX) is currently trading at $2.10 USD, up 3.45% today. Over the past 52 weeks, shares have ranged between $1.48 and $3.15. This page tracks Protalix Biotherapeutics Inc's live share price on the NYSE MKT exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see PLX market cap overview.

Protalix Biotherapeutics Inc (PLX) Stock Price Chart — Daily History & Trading Volume

The chart below tracks Protalix Biotherapeutics Inc's daily closing share price and trading volume on the NYSE MKT exchange over the past year, giving a clear view of recent price momentum and liquidity.

Protalix Biotherapeutics Inc Income Statement — Revenue, Profit & Earnings by Year

Protalix Biotherapeutics Inc's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20252024202320222021
Total Revenue $52.74 Million $53.40 Million $65.49 Million $47.64 Million $38.35 Million
Cost of Revenue $26.99 Million $24.32 Million $22.98 Million $19.59 Million $16.35 Million
Gross Profit $25.75 Million $29.08 Million $42.51 Million $28.05 Million $22.00 Million
Research & Development $19.57 Million $12.97 Million $17.09 Million $29.35 Million $29.73 Million
SG&A $11.68 Million $40.79 Million $25.46 Million $-13.58 Million $-4.02 Million
Total Operating Expenses $31.25 Million $25.16 Million $32.05 Million $41.06 Million $42.46 Million
Operating Income $-5.50 Million $3.92 Million $10.46 Million $-13.01 Million $-20.46 Million
EBITDA $-4.04 Million $6.52 Million $12.94 Million $-10.78 Million $-18.94 Million
EBIT $-5.50 Million $5.22 Million $11.75 Million $-11.87 Million $-20.06 Million
Interest Expense $1.19 Million $1.06 Million $3.18 Million $2.53 Million $7.52 Million
Income Before Tax $-5.61 Million $4.15 Million $8.57 Million $-14.40 Million $-27.58 Million
Income Tax Expense $996.00K $1.22 Million $254.00K $530.00K $6.40 Million
Net Income $-6.60 Million $2.93 Million $8.31 Million $-14.93 Million $-27.58 Million

Protalix Biotherapeutics Inc Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes Protalix Biotherapeutics Inc's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20252024202320222021
Total Assets $82.35 Million $73.42 Million $84.43 Million $55.79 Million $73.67 Million
Total Current Assets $66.67 Million $60.08 Million $69.93 Million $44.88 Million $61.67 Million
Cash & Equivalents $14.68 Million $19.76 Million $23.63 Million $17.11 Million $38.98 Million
Short-term Investments $15.59 Million $15.07 Million $20.93 Million $5.07 Million $38.98 Million
Net Receivables $8.84 Million $2.91 Million $5.27 Million $4.59 Million $3.44 Million
Inventory $25.73 Million $21.24 Million $19.05 Million $16.80 Million $17.95 Million
Property, Plant & Equipment $12.58 Million $10.02 Million $10.88 Million $9.64 Million $9.92 Million
Goodwill
Total Liabilities $34.12 Million $30.21 Million $50.87 Million $66.43 Million $79.70 Million
Total Current Liabilities $26.52 Million $25.62 Million $45.53 Million $32.43 Million $33.18 Million
Long-term Debt $28.19 Million $27.89 Million
Net Debt $-6.36 Million $-14.23 Million $4.06 Million $16.36 Million $-5.51 Million
Total Stockholder Equity $48.23 Million $43.21 Million $33.57 Million $-10.64 Million $-6.04 Million
Retained Earnings $-385.00 Million $-378.39 Million $-381.55 Million $-389.86 Million $-374.93 Million

Protalix Biotherapeutics Inc Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how Protalix Biotherapeutics Inc generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20252024202320222021
Operating Cash Flow $-11.99 Million $8.67 Million $-1.32 Million $-25.00 Million $-10.29 Million
Capital Expenditures $1.64 Million $1.28 Million $1.15 Million $628.00K $1.46 Million
Free Cash Flow $-13.63 Million $7.39 Million $-2.47 Million $-25.63 Million $-11.74 Million
Investing Cash Flow $-2.37 Million $4.22 Million $-16.71 Million $-5.04 Million $18.92 Million
Financing Cash Flow $9.33 Million $-16.79 Million $24.67 Million $8.24 Million $12.08 Million
Dividends Paid
Stock-Based Compensation $2.30 Million $3.25 Million $3.45 Million $2.08 Million $2.38 Million
Depreciation $1.47 Million $1.30 Million $1.19 Million $1.09 Million $1.12 Million
Change in Cash $-4.38 Million $-3.87 Million $6.52 Million $-21.87 Million $20.72 Million

Protalix Biotherapeutics Inc Earnings History — EPS Actual vs. Analyst Estimates

Track Protalix Biotherapeutics Inc's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
May 08, 2026 0.00 0.06 -100.00%
Mar 12, 2026 -0.07 0.04 -300.00%
Nov 13, 2025 0.03 0.07 -57.14%
Aug 14, 2025 -0.04 0.11 -136.36%
May 08, 2025 -0.05 -0.02 -150.00%
Mar 12, 2025 0.09 0.07 +28.57%
Nov 04, 2024 0.03 0.06 -50.00%
Aug 14, 2024 -0.03 0.02 -250.00%